是否逆转:直接口服抗凝药与轻度创伤性脑损伤
本研究为单中心回顾性研究,纳入2016至2024年平地跌倒后孤立性轻度TBI(GCS 13–15)成人273例,其中96例(35%)使用DOAC,41例接受四因子PCC、18例接受andexanet alfa逆转。主要终点影像学出血进展(出血增加>2 mm或24小时内需>2次头颅CT)在DOAC与非DOAC患者间无差异,硬膜下血肿增大47.5% vs 44.8%(p=0.70),需>2次CT 49.1% vs 48.9%(p=1.00)。DOAC使用者中逆转治疗亦未改善影像学进展或次要结局,四因子PCC与andexanet alfa间无显著差异。结论支持对稳定轻度TBI选择性逆转。
要点
- 孤立性轻度TBI(GCS 13–15)平地跌倒患者中,DOAC使用未增加影像学出血进展:硬膜下血肿增大47.5% vs 44.8%(p=0.70)。
- DOAC使用者中药物逆转(四因子PCC或andexanet alfa)未改善影像学进展或GCS下降、ICU住院时间、神经外科干预等次要结局。
- 四因子PCC逆转与andexanet alfa逆转之间未观察到显著结局差异。
- 该研究支持对稳定的轻度TBI患者采取选择性逆转策略,而非对所有DOAC使用者常规逆转。
- 证据等级为Level III(治疗/临床管理),单中心回顾性设计,结论需前瞻性验证。
适用人群与场景
- 成人(18至99岁)孤立性轻度TBI(GCS 13–15)平地跌倒患者,来源于2016至2024年一级创伤中心。
诊断标准与关键阈值
- 轻度TBI定义:Glasgow Coma Scale 13–15。
- 影像学出血进展定义:出血增加>2 mm或24小时内需要>2次头颅CT。
处置流程与药物剂量
- 原文未提及具体逆转药物剂量、给药途径、频次或目标值。
- DOAC使用者中41例接受四因子凝血酶原复合物浓缩物(4F-PCC),18例接受andexanet alfa逆转。
- 研究结论支持对稳定的轻度TBI选择性逆转,而非常规逆转所有DOAC使用者。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 回顾性研究,单中心,纳入273例孤立性轻度TBI平地跌倒成人,96例(35%)使用DOAC。
- 主要终点影像学出血进展:DOAC与非DOAC患者硬膜下血肿增大47.5% vs 44.8%(p=0.70),需>2次CT 49.1% vs 48.9%(p=1.00),均无显著差异。
- DOAC使用者中逆转治疗未与改善影像学进展或次要结局相关。
- 四因子PCC与andexanet alfa逆转间无显著结局差异。
- 次要结局包括GCS下降、ICU住院时间、神经外科干预、血栓栓塞事件、出院去向及住院死亡率,原文未给出具体数值。
证据类型、等级与局限
- 证据类型:单中心回顾性队列研究(治疗/临床管理)。
- 证据等级:Level III。
- 局限:回顾性设计、单中心、样本量273例,原文未提及前瞻性验证。
对床旁实践的改变
- 对平地跌倒后孤立性轻度TBI(GCS 13–15)的稳定DOAC使用者,可考虑选择性逆转而非常规药物逆转,因逆转未显示可测量的早期结局获益。
- 不适用于非孤立性TBI、非轻度TBI(GCS<13)、非平地跌倒机制或血流动力学不稳定患者,原文未纳入这些人群。
- 常见陷阱:将本回顾性研究的无获益结论外推至所有DOAC相关TBI或作为决策阈值;原文结论仅支持选择性逆转,未给出具体选择标准。
指南或共识出处
- J Trauma Acute Care Surg. 2026;00:000-000. DOI未提供。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The growing usage of direct oral anticoagulants (DOACs) has brought into question the need for pharmacologic reversal in patients who develop traumatic brain injuries (TBIs). While there are specific benefits in reversal for TBI patients on warfarin, the impact has not been clearly shown in DOAC populations. This study evaluated radiographic and clinical outcomes among patients with isolated mild TBIs to determine whether DOAC usage or its reversal confers measurable differences in early outcomes.
METHODS: We conducted a retrospective review of adults (18 to 99 y) with isolated mild TBI (Glasgow Coma Scale: 13 to 15) after ground-level falls at a Level I trauma center from 2016 to 2024. The primary outcome was radiographic hemorrhage progression, defined as >2-mm increase in hemorrhage or need for >2 head computed tomographies within 24 hours. Secondary outcomes included Glasgow Coma Scale decline, intensive care unit length of stay, neurosurgical intervention, thromboembolic events, disposition, and inpatient mortality. Multivariable logistic regression and propensity score matching were used to evaluate associations between DOAC usage, reversal therapy, and outcomes.
RESULTS: Among 273 patients, 96 (35%) were taking a DOAC, and of these, 41 received four-factor prothrombin complex concentrate and 18 received andexanet alfa. DOAC patients demonstrated similar rates of radiographic progression, intensive care unit length of stay, and discharge disposition compared with non-DOAC patients. In multivariate analysis, DOAC usage was not associated with increased radiographic progression, measured by subdural hemorrhage growth (47.5% vs. 44.8%; p = 0.70) or increased need for >2 computed tomography scans (49.1% vs. 48.9%, p = 1.00). Among DOAC users, reversal was also not associated with improved radiographic progression or secondary outcomes. No significant outcome differences were observed between reversal with four-factor prothrombin complex concentrate and andexanet alfa.
CONCLUSIONS: In isolated mild TBI after ground-level falls, DOAC usage was not associated with worsened clinical outcomes or increased radiographic progression. Pharmacologic reversal offered no measurable benefit. These findings support selective reversal in stable mild TBI. ( J Trauma Acute Care Surg . 2026;00: 000-000 Copyright © 2026 Wolters Kluwer Health, LLC. All rights reserved.).
LEVEL OF EVIDENCE: Therapeutic/Care Management; Level III.
参考来源
- Chen LB, Stiffler M, Pawar OS, et al. To reverse or not to reverse: Direct oral anticoagulants in mild traumatic brain injury. J Trauma Acute Care Surg. 2026. PMID: 42468510. doi:10.1097/TA.0000000000005133
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。